As per our report, the global atopic dermatitis market size was valued at USD 11.77 billion in 2022. It is expected to grow at a CAGR of 13.13% and be worth USD 21.80 billion by 2027. Therefore, the market is expected to progress at a modest pace through the forecast period.
Atopic Dermatitis is an inflammatory skin disease, and the degree of its severity varies from patient to patient. It usually begins in childhood and is mainly confined to the flexural surfaces of the body. It is highly prevalent and is more commonly known as eczema. Itching, redness of the skin, cracking, weeping, etc., are symptoms, and it is a long-term disease. Low humidity, cold weather, and seasonal allergies are the common causes of it, and the pattern of the disease and its severity determine the kind of treatment it ought to receive.
Y-O-Y growth in the incidence of atopic dermatitis, the launch of biologics & small molecules, premium-priced drugs substituting generic first-line and second-line therapeutics, and improved diagnostics are expected to stoke the growth of the global atopic dermatitis market.
Growing incidences of skin allergies and chronic disorders elevate the market's growth rate to the extent. Atopic dermatitis disease severity ranges from patient to patient, and the treatment procedures involve the severity degree. Escalating expenditure on healthcare and the growing popularity of these treatment procedures through digital advertisements accelerates the growth rate of the global atopic dermatitis market.
Additionally, a growing number of initiatives from various governments in improving the infrastructure of hospitals and clinics with the latest equipment are expected to expand the growth scope for the global atopic dermatitis market. Furthermore, an increasing number of patients suffering from various skin disorders, changes in climatic conditions, and the rise in disposable income in both developed and developing countries are further expected to accelerate the market's growth rate. Besides, the emergence of the latest technologies in the medical sector and the introduction of innovative procedures magnify this market's growth.
Rising complications and side effects after the treatment procedure in some people hinder the demand of the global atopic dermatitis market.
The shortage of skilled people in hospitals and clinics and fluctuations in the economic strategies negatively impact the growth rate of the atopic dermatitis market. In addition, less availability of necessary equipment in rural areas remains a challenging factor for the market players. Also, the high cost of the treatment procedures due to advanced features is declining the growth rate of this market.
Impact of COVID-19 on the global atopic dermatitis market:
The sudden outburst of the new coronavirus (COVID-19) was caused by the severe acute respiratory syndrome SARS-CoV-2 reagent. The pandemic crisis has affected every industry in terms of profit or production. Atopic dermatitis doesn't affect critical markers' regularity in patients hospitalized with coronavirus. Adults with atopic diseases are at significant risk of lower respiratory tract infections (LRTIs) and Upper respiratory tract infections (URTIs) than those without atopic diseases. Patients infected with coronavirus didn't face any difficulties during their infection course. Moreover, patients with atopic dermatitis are said to have an efficient and safe therapy with dupilumab. During the COVID-19 pandemic period, the market teledermatology has increased due to a drop in the frequent clinical visits because of sanitary restrictions. Most of the patients with Atopic Dermatitis (AD) continue their generalized treatment, and patients should not stop their oral and biological therapy or other existing treatments without consulting their physicians. As per the National Eczema Association, the coronavirus (COVID-19) pandemic crisis doesn't increase the threat of life-threatening issues in people with eczema. On the other hand, people with atopic dermatitis have higher incidences of anxiety and depression, and patients are found to account for increased occurrences in the emergency department. All these factors are expected to accelerate the growth rate of the global atopic dermatitis market during the forecast period.
Market Size Available
2021 to 2027
2022 to 2027
By Treatment Type, Route of Administration, Distribution channel, and Region.
Various Analyses Covered
Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities
North America, Europe, APAC, Latin America, Middle East & Africa
This market research report on the global atopic dermatitis market has been segmented and sub-segmented into the following categories and analyzed market size and forecast until 2026.
Atopic Dermatitis Market - By Treatment Type:
Based on treatment type, the drug treatment segment holds the highest market share with the rise in the prevalence of early diagnosis diseases. In addition, investments in research and development institutes to improve healthcare centers' services bolstered the market's growth rate.
Atopic Dermatitis Market - By Route of Administration:
Based on the administration route, the topical segment leads with a dominant market share, whereas the oral segment will have the highest CAGR in the coming years. Support from public and private organizations over managing all the operations in the hospitals and clinics only to provide effective treatment procedures is expanding the market share.
Atopic Dermatitis Market - By Distribution Channel:
Based on the distribution channel, the hospital pharmacies segment is ruling with the highest market share due to the increasing scale of hospitals and clinics worldwide. The growing flow of patients to hospitals fuels the demand for the global Atopic Dermatitis Market.
Atopic Dermatitis Market – By Region:
Geographically, the North American atopic dermatitis market is expected to be the market leader in the global atopic dermatitis treatment market during the forecast period. New product launches, early treatment adoption, and lifestyle changes are the reasons behind it.
Globally, the European atopic dermatitis market is predicted to be the second-largest regional market between 2020 to 2025. Heavy investment in R&D activities in this region is the cause of the observable trend mentioned above. As a result, some European countries like Spain and the United Kingdom are expected to showcase promising growth from 2020 to 2025.
The Asia Pacific atopic dermatitis market is predicted to be the fastest-growing global atopic dermatitis treatment market in the aforementioned forecast period. Japan is forecasted to register the highest CAGR during the same period. This extension of the region can be attributed to victims' significant unmet clinical needs, increasing spending on healthcare, and adequate treatment availability.
The Latin American atopic dermatitis market is expected to grow significantly in the next five years due to a rapidly growing population, changing lifestyles, and a paradigm shift towards western lifestyles; increasing R&D and a large target patient pool are attributable to the observable trend mentioned above.
The MEA atopic dermatitis market is anticipated to undergo sluggish growth in the aforementioned forecast period.
KEY MARKET PARTICIPANTS:
Some of the notable companies operating in the global atopic dermatitis market profiled in this report are Astellas Pharma Inc., Valeant Pharmaceuticals International, Inc., Sanofi S.A., Anacor Pharmaceuticals, Inc.., Meda Pharmaceuticals, Regeneron Pharmaceuticals Inc., Novartis International AG, and Pfizer Inc.
RECENT MARKET DEVELOPMENTS:
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Treatment Type
5.1.2 Drug Treatment
18.104.22.168 Calcineurin Inhibitors
5.1.3 Radiation Treatment
5.1.4 Y-o-Y Growth Analysis, By Treatment Type
5.1.5 Market Attractiveness Analysis, By Treatment Type
5.1.6 Market Share Analysis, By Treatment Type
5.2 Route of administration
5.2.4 Y-o-Y Growth Analysis, By Route of administration
5.2.5 Market Attractiveness Analysis, By Route of administration
5.2.6 Market Share Analysis, By Route of administration
5.3 Distribution Channel
5.3.2 Hospital Pharmacies
5.3.3 Retail Pharmacies
5.3.4 Online Pharmacies
5.3.5 Y-o-Y Growth Analysis, By Distribution Channel
5.3.6 Market Attractiveness Analysis, By Distribution Channel
5.3.7 Market Share Analysis, By Distribution Channel
6. Geographical Analysis
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
22.214.171.124 By Geographical Area
126.96.36.199 By Treatment Type
188.8.131.52 By Route of administration
184.108.40.206 By Distribution Channel
6.1.4 Market Attractiveness Analysis
220.127.116.11 By Geographical Area
18.104.22.168 By Treatment Type
22.214.171.124 By Route of administration
126.96.36.199 By Distribution Channel
6.1.5 Market Share Analysis
188.8.131.52 By Geographical Area
184.108.40.206 By Treatment Type
220.127.116.11 By Route of administration
18.104.22.168 By Distribution Channel
6.2 North America
6.2.2 United States
6.4.6 South Korea
6.5 Latin America
6.5.5 Rest of Latin America
6.6 Middle East & Africa
7. Strategic Analysis
7.1 PESTLE analysis
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Astellas Pharma Inc.
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Sanofi S.A.
8.3 Valeant Pharmaceuticals International, Inc.
8.4 Novartis International AG
8.5 Pfizer Inc.
8.6 Meda Pharmaceuticals
8.7 Regeneron Pharmaceuticals Inc.
8.8 Anacor Pharmaceuticals, Inc.
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, Collaborations, and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
a) List of Tables
b) List of Figures
As per our research report, the global atopic dermatitis market size was valued at USD 11.77 billion in 2022 and is estimated to grow by USD 21.8 billion by 2027.
Based on the treatment type, the drug type accounted for the major share of the global atopic dermatitis market in 2021.
Among all the regions, the North American region was the leader in the global atopic dermatitis market in 2021.
Astellas Pharma Inc., Valeant Pharmaceuticals International, Inc., Sanofi S.A., Anacor Pharmaceuticals, Inc.., Meda Pharmaceuticals, Regeneron Pharmaceuticals Inc., Novartis International AG, and Pfizer Inc. are a few of the noteworthy companies in the global atopic dermatitis market.
Talk to our analyst and get customised report done according to your research needs
Check if you can avail any discount. Submit your details and our team will get back to you.
Request to avail a free sample report that reflects this market and its growth.